A different Cadillac
Don't let the words “large, luxury sedan” fool you.
The largest sedan in Cadillac's lineup, the 2013 XTS, handles with the poise and competence of a smaller car and with a smoothness not typically found in high-end, sporty sedans.
The modern, top-notch interior design of the XTS — complete with front seats that can have some of the biggest thigh support extenders in the business — is the best to come from Cadillac in years.
But it takes practice to use the new Cue information display with touchscreen. And even reaching over to pick up a purse that falls on the passenger-side floor can cause the radio to change channels, if only because the driver's hair accidentally brushes a display screen.
The XTS exterior is pleasing, as years of Cadillac's sharp-edge styling is smoothed for more graceful lines.
The XTS earned top, five out of five stars across the board in federal government frontal, side and overall crash test ratings.
This rating didn't take into account the fact the XTS is first with a safety alert seat that vibrates the driver's bottom if the system senses the car may be backing into an obstacle or moving into an adjacent lane that's already occupied.
Perhaps best of all, the new-for-2013, five-passenger XTS has a starting retail price of $44,995 with front-wheel drive and $51,835 with all-wheel drive. All models come with a 304-horsepower, direct-injection V-6 and six-speed automatic transmission.
Competitors include the 2013 Lincoln MKS sedan, which has a starting manufacturer's suggested retail price, including destination charge, of $43,685 with front-wheel drive, 304-horsepower V-6 and six-speed automatic.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Nonprofit Concordia Lutheran Ministries adjusts to marketplace realities
- Pittsburgh region’s unemployment rate stays steady
- GNC will expand its testing of supplements in settlement with NY
- Heinz merging with Kraft in mega-deal; headquarters to stay in Pittsburgh
- Consumer spending inches up in February as income soars
- Stocks gain on encouraging signs in spending and home sales
- Stop foreign dumping, U.S. Steel CEO Longhi tells Congress
- Venting online about job protected
- Falling demand for steel not likely to reverse any time soon
- UnitedHealth bulks up for prescription drug cost fight
- Dow Chemical, Olin in $5B cash-and-stock deal